Suggestions
Laura Soucek
Biomedical researcher and entrepreneur based in Barcelona
Laura Soucek is a prominent cancer researcher and entrepreneur based in Barcelona, Catalonia, Spain. Here are some key details about her:
Professional Roles
- Member at referentsfemenins.cat since April 20231
- Director of the Preclinical and Translational Research Program at Vall d'Hebron Institute of Oncology (VHIO) since March 20221
- Head of Models of Cancer Therapies Laboratory at VHIO since March 20111
- Research Professor at ICREA since October 20141
- Founder and Chief Executive Officer of Peptomyc since December 20141
- Associate Professor at Universitat Autònoma de Barcelona since 20141
Research Focus
Laura Soucek specializes in cancer research, particularly focusing on the Myc oncoprotein. Her work involves developing innovative treatments to inhibit Myc in cancer cells.3 She has designed a Myc dominant negative called Omomyc to investigate the therapeutic benefits of Myc inhibition in various cancer types.3
Education
- PhD in Genetics and Molecular Biology from Sapienza Università di Roma (1997-2000)1
- University Degree in Biology, specialized in Biotechnology from Sapienza Università di Roma (1991-1996)1
Achievements
- Recipient of the FIDEM Award 2019 in the Science category1
- Awarded several research grants, including an ERC Consolidator Grant (2014-2019)2
- Founded Peptomyc S.L., a spin-off company developing anti-Myc cell penetrating peptides for cancer treatment14
Laura Soucek's work combines academic research with entrepreneurial efforts to translate scientific discoveries into potential cancer therapies. Her involvement with referentsfemenins.cat likely reflects her role as a prominent female scientist and entrepreneur in Catalonia.
Highlights
I am happy to share our latest review in Signal Transduction and Targeted Therapy (Nature Portfolio) on #RAS and #MYC cooperation, co-authored by Sílvia Casacuberta Serra, Íñigo G. and Daniel Capitán Leo. RAS and MYC are two of the most commonly altered oncogenes in cancer. Their interplay is crucial in tumor development, regulating all cancer hallmarks. Despite they have been considered "undruggable" for a very long time, recent advances show promise in targeting them. This review delves into their complex partnership and the latest clinical trials of RAS and MYC inhibitors. A paradigm shift in cancer therapy! 🧬🔬 #CancerResearch #Oncogenes #CancerTherapy #ClinicalTrials https://rdcu.be/dRvpf
I am happy to share this recent publication, result of a nice collaboration with Arturo Sala and Gianluca Sala, showing that #Omomyc can be functionalized by fusion with antibodies to favor tumor targeting. https://lnkd.in/dcrmrdA9 Vall d'Hebron Institute of Oncology (VHIO), Institució Catalana de Recerca i Estudis Avançats, ICREA, Peptomyc
